Inclusion Criteria:

          -  Adults 18 years of age or older;

          -  Female participants of childbearing potential must agree to use a highly effective
             form of contraception;

          -  Histological or cytological documentation of locally advanced, recurrent, or
             metastatic solid malignancy;

          -  Disease that has progressed after standard therapy for the specific tumor type, or for
             which standard therapy has proven to be ineffective, intolerable, or is considered
             inappropriate, or if no further standard therapy exists;

          -  Participants must provide a tumor biopsy during the screening period from a tumor
             lesion and agree to an additional on-treatment biopsy.

          -  Measurable disease per RECIST 1.1

          -  Eastern cooperative oncology group (ECOG) performance status (PS) 0 to 1

          -  Life expectancy of at least 12 weeks.

          -  Adequate organ function as determined by laboratory assessments.

          -  Adequate cardiac ejection fraction as measured by echocardiogram.

        Exclusion Criteria:

          -  Prior anti-cancer treatment including investigational agents, immune checkpoint
             inhibitors, chemotherapy, targeted therapy, and biological therapy: within 4 weeks or
             5 half-lives of the drug, whichever is shorter.

          -  Prior allogenic or autologous bone marrow transplantation or other solid organ
             transplantation.

          -  Toxicity from previous anticancer treatment, including; greater than or equal to Grade
             3 immune-mediated toxicity considered related to prior immunotherapy and that led to
             treatment discontinuation; or toxicity related to prior treatment that has not
             resolved.

          -  Known additional malignancy that progressed or required active treatment within the
             last 2 years.

          -  Uncontrolled or symptomatic central nervous system (CNS) metastases and/or
             carcinomatous meningitis.

          -  Active autoimmune disease that has required systemic disease-modifying or
             immunosuppressive treatment within the last 2 years.

          -  Concurrent medical condition requiring the use of systemic immunosuppressive
             treatment.

          -  Cirrhosis or current unstable liver or biliary disease per investigator assessment.

          -  Active infection requiring systemic treatment, known human immunodeficiency virus
             infection, or positive test for hepatitis B surface antigen (HBsAg) or hepatitis C
             virus (HCV)

          -  Prolonged QT corrected for heart rate according to Fridericia's formula as measured by
             electrocardiogram.

          -  History of hypersensitivity to monoclonal antibodies. For combination therapy, history
             of hypersensitivity to dostarlimab or its excipients.

          -  History or evidence of significant cardiovascular (CV) risk.

          -  Recent history (within 6 months) of uncontrolled symptomatic ascites or pleural
             effusions.

          -  History of idiopathic pulmonary fibrosis; interstitial lung disease; organizing
             pneumonia; noninfectious pneumonitis that required steroids, or evidence of active,
             noninfectious pneumonitis.

          -  Pregnant or lactating woman.

          -  Receipt of live vaccine within 30 days of the start of study intervention.

          -  Receipt of transfusion of blood products or administration of colony-stimulating
             factors within 14 days before the first dose of study intervention.

          -  Major surgery less than 4 weeks before the first dose of study intervention.

          -  Known drug or alcohol abuse.